As it pushes toward its goal of being a top 5 animal health player by 2020, Ceva Animal Health has signed a pheromone R&D pact with insect repellant specialist M2i Life Sciences.
The 10-year arrangement between the two companies will center around the development of “formulations and innovative systems” to utilize pheromones in animal health, according to a press release. M2i is a top player in pheromone applications for agriculture, according to the release.
Ceva is already a player in pheromone products with Feliway and Adaptil to treat behavior issues in cats and dogs, respectively. The products are synthetic version of pheromones, which are naturally-occurring molecules suspected to have a calming impact on animals. As of 2014, Ceva’s pheromone-based products were supported by 42 clinical studies, the company's website says.
For Ceva, the partnership comes in quick succession after its deal last week to buy France’s Biovac. Through that purchase, Ceva picked up Biovac’s “autogeneous” vaccine technology and allergy treatment offerings.
Overall, the moves are part of a larger effort by Ceva to compete at the top level in animal health, with Ceva CEO Marc Prikazsky having previously said he’s shooting to break into the top 5 by the end of the decade.
- here's the release (PDF)
Related Articles:
Ceva vows an ‘extremely responsive’ approach to U.S. animal health market
Ceva Animal Health expanding into swine market